The Valley Desk

NCT03794349 · Interventional trial

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Overall registry status Active not recruiting

Phase 2

Conditions High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov